100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series

Journal of the American Academy of Dermatology

Volumn 73, Issue 4, 2015, Pages 645-654

  Shi, Vivian Y ^a   Tran, Khiem ^a   Patel, Forum ^a   Leventhal, Jonathan ^d   Konia, Thomas ^a   Fung, Maxwell A ^a   Wilken, Reason ^a   Garcia, Miki Shirakawa ^a   Fitzmaurice, Sarah D ^c   Joo, Jayne ^a   Monjazeb, Arta M ^a   Burrall, Barbara A ^a   King, Brett ^d   Martinez, Steve ^b   Christensen, Scott D ^e   Maverakis, Emanual ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d YALE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

imiquimod; interleukin; intralesional; metastatic melanoma; pemphigus vulgaris; retinoid

Indexed keywords

CARBOPLATIN; DACARBAZINE; IMIQUIMOD; INTERLEUKIN 2; PACLITAXEL; RETINOID; VEMURAFENIB; AMINOQUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; DECREASED APPETITE; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HYPOTENSION; LONG TERM CARE; MALE; METASTATIC MELANOMA; MIDDLE AGED; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RIGOR; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; URTICARIA; VERY ELDERLY; COHORT ANALYSIS; DRUG COMBINATION; EVALUATION STUDY; INTRALESIONAL DRUG ADMINISTRATION; MELANOMA; METASTASIS; PATHOLOGY; RISK ASSESSMENT; SECONDARY; SKIN NEOPLASMS; TOPICAL DRUG ADMINISTRATION; TUMOR INVASION;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MALE; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; RETINOIDS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84941599887     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.06.060     Document Type: Article

References (15)

1. C.M. Balch, J.E. Gershenwald, S.J. Soong, and et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 36 2009 6199 6206
2. E. Maverakis, L.A. Cornelius, G.M. Bowen, and et al. Metastatic melanoma-a review of current and future treatment options Acta Derm Venereol 95 5 2014 516 524
3. P. Radny, U.M. Caroli, J. Bauer, and et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases Br J Cancer 89 9 2003 1620 1626
4. K.U. Boyd, B.M. Wehrli, and C.L. Temple Intra-lesional interleukin-2 for the treatment of in-transit melanoma J Surg Oncol 104 7 2011 711 717
5. D.S. Green, M.D. Bodman-Smith, A.G. Dalgleish, and M.D. Fischer Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma Br J Dermatol 156 2 2007 337 345
6. B. Weide, E. Derhovanessian, A. Pflugfelder, and et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma Cancer 116 17 2010 4139 4146
7. M.S. Garcia, Y. Ono, S.R. Martinez, and et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream Melanoma Res 21 3 2011 235 243
8. F. Patel, R. Wilken, B. Burrall, and et al. Detailed protocol for administration of intralesional IL-2 for the treatment of stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines Dermatol Online J 20 11 2014
9. A. Safwat, N. Aggerholm, I. Roitt, J. Overgaard, and M. Hokland Tumor burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2 Eur J Cancer 40 9 2004 1412 1417
10. T. Yamamoto, E. Ueta, and T. Osaki Apoptosis induction by interleukin-2-activated cytotoxic lymphocytes in a squamous cell carcinoma cell line and Daudi cells-involvement of reactive oxygen species-dependent cytochrome c and reactive oxygen species-independent apoptosis-inducing factors Immunology 110 2 2003 217 224
11. K.B. Gorden, K.S. Gorski, S.J. Gibson, and et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8 J Immunol 174 3 2005 1259 1268
12. F. Palamara, S. Meindl, M. Holcmann, P. Luhrs, G. Stingl, and M. Sibilia Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod J Immunol 173 5 2004 3051 3061
13. M.A. Hyde, M.L. Hadley, P. Tristani-Firouzi, D. Goldgar, and G.M. Bowen A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions Arch Dermatol 148 5 2012 592 596
14. D.S. Green, A.G. Dalgleish, N. Belonwu, M.D. Fischer, and M.D. Bodman-Smith Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma Br J Dermatol 159 3 2008 606 614
15. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma J Clin Oncol 24 7 2006 1169 1177